Daewoong Pharmaceutical, Stock Price -1.8% at This Time... 18,103 Shares Net Bought by Individuals in the Last 5 Days

As of 10:31 AM on the 2nd, Daewoong Pharmaceutical is trading at 109,000 KRW, down 1.8% from the previous day. The trading volume is 135,474 shares, which is 5.28% of the previous day's volume. Daewoong Pharmaceutical is known as a leading pharmaceutical company manufacturing and selling medicines such as Urusa and Albis.

On December 1st, Shin Jae-hoon, a researcher at Hanwha Investment & Securities, stated, "The result of the ITC (International Trade Commission) lawsuit between Daewoong Pharmaceutical and Medytox regarding botulinum toxin has been rescheduled to December 16th. Attention is focused on how the previously recommended 10-year import ban from the preliminary results will change. Various scenarios are expected, including a reduction in the import ban period, damages to Evolus, or a ruling different from the preliminary results. Ultimately, on December 16th, the conclusion of this long battle will be reached, which is expected to resolve uncertainties for both companies." He set Daewoong Pharmaceutical's target price at 120,000 KRW.

Over the past five days, individual investors have net purchased 18,103 shares of Daewoong Pharmaceutical, while foreign investors and institutions have net purchased 6,958 shares and net sold 13,321 shares, respectively.

※ Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an article automation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.